Diamyd Medical AB (publ) (STO: DMYD.B)

Market Cap	1.64B
Revenue (ttm)	185.00K
Net Income (ttm)	-139.62M
Shares Out	99.72M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	166,360
Open	16.46
Previous Close	16.46
Day's Range	16.10 - 16.98
52-Week Range	6.41 - 25.00
Beta	2.12
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 9, 2024

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 25
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DMYD.B

Financial Performance

In 2023, GENO's revenue was 159.07 million, an increase of 53.60% compared to the previous year's 103.56 million. Earnings were 61.50 million, an increase of 449.55%.